Elan Ezickson (file photo)
December 4, 2020 10:50 AM EST
Pharma

Zio­phar­m's ac­tivist dra­ma con­tin­ues as an­oth­er board mem­ber mem­ber re­signs. Is the end in sight?

Max Gelman

Senior Editor

The very pub­lic and very bit­ter fight be­tween Zio­pharm On­col­o­gy and a mi­nor­i­ty ac­tivist in­vestor con­tin­ued Fri­day with the res­ig­na­tion of a board mem­ber …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

For CDC, Trump picks Dave Wel­don, a for­mer con­gress­man who pushed for vac­cine in­jury claims

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

A service from the Financial Times